Share

EORTC members to receive free eBook access to Touch Briefings

Touch_Oncology_logo

As part of a Media partnership with Touch Briefings, EORTC members receive free eBook access to Touch Briefings ‘EU Oncology and Haematology’ Volume 7 Issue 3

European Oncology & Haematology is a peer-reviewed quarterly journal that includes review articles, case reports, practice guidelines and original research. Guided by an Editorial Board of world-renowned physicians, European Oncology & Haematology comprises articles from recognised thought leaders to provide concise and timely update on the latest opinion and advances spanning the breadth of oncology and haematology practice. In this edition – Volume 7 Issue 3 – Giovanni Di Vagno explores “what’s new in gynaecological oncology”, in his review article of the same title. Meanwhile, Catherine Terret and Jean-Pierre Droz investigate the questionnaires and tools available to evaluate quality of life in elderly patients with urological malignancies and Maria Cappellini and colleagues review thalassemia as a hypercoagulable state and examine the molecular and cellular mechanisms that lead to this, plus much more.

To access the current edition in full and free eBook format, please click here.

For more information please visit: www.touchoncology.com

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023